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Abstract
Background:  Variation in the COMT gene has been implicated in a number of psychiatric
disorders, including psychotic, affective and anxiety disorders. The majority of these studies have
focused on the functional Val108/158Met polymorphism and yielded conflicting results, with limited
studies examining the relationship between other polymorphisms, or haplotypes, and psychiatric
illness. We hypothesized that COMT variation may confer a general risk for psychiatric disorders
and have genotyped four COMT variants (Val158Met, rs737865, rs165599, and a SNP in the P2
promoter [-278A/G; rs2097603]) in 394 Caucasian cases and 467 controls. Cases included patients
with schizophrenia (n = 196), schizoaffective disorder (n = 62), bipolar disorder (n = 82), major
depression (n = 30), and patients diagnosed with either psychotic disorder NOS or depressive
disorder NOS (n = 24).
Results: SNP rs2097603, the Val/Met variant and SNP rs165599 were significantly associated (p =
0.004; p = 0.05; p = 0.035) with a broad "all affected" diagnosis. Haplotype analysis revealed a
potentially protective G-A-A-A haplotype haplotype (-278A/G; rs737865; Val108/158Met;
rs165599), which was significantly underrepresented in this group (p = 0.0033) and contained the
opposite alleles of the risk haplotype previously described by Shifman et al. Analysis of diagnostic
subgroups within the "all affecteds group" showed an association of COMT in patients with
psychotic disorders as well as in cases with affective illness although the associated variants differed.
The protective haplotype remained significantly underrepresented in most of these subgroups.
Conclusion:  Our results support the view that COMT variation provides a weak general
predisposition to neuropsychiatric disease including psychotic and affective disorders.
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Background
The role of Catechol-O-Methyltransferase (COMT) in
dopamine metabolism has led to investigation of its vari-
ants in the etiology of numerous psychiatric disorders
including psychotic, affective and anxiety disorders. The
largest body of work exists for schizophrenia and bipolar
disorder because 1. Imbalance of dopamine is thought be
key to the pathogenesis of psychosis [1,2], 2. COMT is
located in the region on chromosome 22q11 commonly
deleted in velo-cardio-facial/DiGeorge syndrome (VCFS/
DGS) whose phenotypic spectrum includes severe psychi-
atric disease that has been described as schizophrenia by
some [3-5] and bipolar disorder by others [6] and 3.
Genetic variation in COMT has been implicated in pre-
frontal cortical function [7,8], which is commonly
impaired in both disorders [9]. In addition to schizophre-
nia and bipolar disorder, evidence for a contribution of
COMT variants exists for panic disorder [10,11], attention
deficit hyperactivity disorder [12], obsessive compulsive
disorder [13], phobic anxiety [14] and anorexia nervosa
[15].
Most studies focused on a common functional SNP
(Val108/158Met) because the Methionine-containing
variant shows a significant reduction in enzyme activity
[16-18]. However, despite their large number, these stud-
ies have generated controversial and confusing results: For
schizophrenia, initial studies have reported an association
of the A (Met) allele [19-21]. However, current evidence
favors an association of the of the G (Val) allele [22-27].
Similarly, for bipolar disorder, several studies reported an
association of Met-COMT [[28-31], reviewed in: [32]]; but
a recent study by Shifman et al. showed evidence of an
association of Val-COMT [33]. As with schizophrenia and
bipolar disorder, the associations remain controversial for
other psychiatric illnesses including ADHD, OCD, ano-
rexia nervosa, and anxiety disorder [34-37]. In all cases,
likely contributing factors are small sample sizes and/or
diagnostic differences as the absence of objective biomar-
kers in psychiatric disorders potentially hampers consist-
ent classification of disease [38,39].
Although Shifman et al. saw an association of the Valine
allele in their cohort, its moderate effect combined with
highly significant p-values for two SNPs located in intron
1 and the 3'UTR (rs737865 and rs165599) has led to the
hypothesis that the Val/Met variant may not contribute to
disease but may simply be in strong LD with the actual, as
of yet unidentified pre-disposing variant [40]. A recent
study by Handoko et al. supports this view [41].
The COMT gene is transcribed from two promoters result-
ing in a cytoplasmatic form (soluble; S-COMT, tran-
scribed from P1) and a membrane bound form (MB-
COMT, transcribed from P2) [42]. Although both variants
are widely expressed at varying levels, MB-COMT appears
to be the predominant from in brain [42,43]. It has there-
fore been suggested that disease pre-disposing variant/s
may be located in the P2 promoter, acting in cis to alter
COMT protein levels via enhancement or suppression of
transcription [44]. Several recent studies have investigated
the effect of previously associated variants on COMT
expression levels [16,45-47]. Interestingly, some showed
reduced expression levels of Valine-coding COMT mRNAs
[45,47]. Although this contrasts with the higher enzyme
activity of Val-COMT, the net result of these two effects
seems to be a 40% higher enzyme activity in human dor-
solateral prefrontal cortex samples homozygous for Val-
COMT [16]. A variant located in the P2 promoter (-278A/
G) showed a small effect on enzyme activity, suggesting
that it may indeed influence brain dopamine levels [16].
Taken together, current evidence suggests that COMT var-
iants may provide a weak predisposition to a variety of
psychiatric conditions via alteration of dopamine levels in
the prefrontal cortex (supported by the association of the
same haplotype with both, schizophrenia and bipolar dis-
order) [33]. Expression of specific disorders may require
the presence of additional predisposing variants in sus-
ceptibility genes specific for these pathologies. Therefore,
we have tested the relationship between COMT variation
and psychiatric illness in a large cohort of Caucasian
patients. We included subjects with a range of psychiatric
diseases, and genotyped 4 SNPs including the Val/Met
polymorphism, the P2 promoter SNP (-278A/G,
rs2097603) as well as SNPs rs737865 and rs165599 to test
the hypothesis that COMT genetic variation is associated
with the risk for psychiatric illness. We analyzed the rela-
tionship between four-marker haplotypes, as well as the
individual SNPs. Moreover, we conducted exploratory
analyses of specific diagnostic subgroups within the
cohort to assess the relationship between COMT and var-
ious psychiatric diagnoses.
Methods
Study Subjects
The sample was comprised of 394 US-Caucasian cases
(mean age = 39.4 years; 35.7% females/64.3% males).
Diagnostic categories included schizophrenia (n = 196),
schizoaffective disorder (n = 62), bipolar disorder (n =
82), major depression (n = 30), psychotic disorder NOS
(19) and depressive disorder NOS (5). The control group
consisted of 467 Caucasian individuals (mean age = 39.3
years, 51.8% females/48.2% males). Cases were recruited
from the inpatient and outpatient clinical services of the
Zucker Hillside Hospital, a division of the North Shore –
Long Island Jewish Health System, where patients are
screened for potential recruitment into research studies by
the Clinical Assessment and Training Unit (CAT) of the
NIH-funded Hillside Hospital Intervention ResearchBehavioral and Brain Functions 2005, 1:19 http://www.behavioralandbrainfunctions.com/content/1/1/19
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Center. The CAT monitors the inpatient and outpatient
hospital census daily and conducts preliminary screening
and recruitment functions. Inclusion criteria for screening
for this study included a clinical diagnosis of a psychotic
disorder, no active substance abuse, and ability to provide
informed consent. After obtaining written informed con-
sent, each subject was assessed with the Structured Clini-
cal Interview for DSM-IV Axis I Disorders (SCID: version
2.0, 8/98), administered by trained raters. Standardized
diagnostic assessments were supplemented with clinical
information obtained by review of medical records and
interviews with family informants when possible, and all
diagnostic information was compiled into a narrative case
summary. Information on the onset and course of Axis I
illness, presence of Axis II pathology, presence of Axis III
diagnoses, and a brief description of the subject's psycho-
social and occupational functioning during the course of
illness was presented to a consensus diagnostic committee
consisting of a minimum of three senior faculty with
DSM-IV diagnostic experience, as well as other faculty and
trainees with SCID experience. All available information
was used to arrive at a consensus DSM-IV diagnosis.
Healthy controls were ascertained and recruited by the
Zucker Hillside Hospital Normal Control Program.
Potential participants were recruited via local newspaper
advertisements, flyers and community internet resources
and underwent initial telephone screening to assess eligi-
bility criteria. Subjects meeting eligibility criteria were
administered the SCID – NP to rule out the presence of an
Axis I psychiatric disorder, urine toxicology screen for
drugs of and a family history of psychiatric disorder
assessment. Exclusion criteria included current or past:
Axis I psychiatric disorder, psychotropic drug treatment,
substance abuse, first-degree family member with an Axis
I psychiatric disorder, or inability to provide written
informed consent. A subset of the control cohort was col-
lected through the Massachusetts General Hospital Clini-
cal Research Program in conjunction with the Harvard-
Partners Center for Genetics and Genomics in Boston,
MA. This subset comprised disease free subjects over the
age of 18. For the purposes of the study, "disease" was
defined as current or past diagnoses made by a medical
care provider that required medication or other forms of
treatment/therapy. With the exception of orthopedic pro-
cedures, appendectomy, or those that were trauma
related, surgery was considered an exclusionary criterion.
Subjects who took prescription medications or regularly
used over the counter medications were also excluded.
These subjects completed a structured family and medical
questionnaire that detailed current and past history of
psychiatric illness and pharmacological or psychothera-
peutic psychiatric treatment. All responses to the self-
report form were confirmed by clinical interview by phy-
sicians. Physical exams were completed at the study visit.
This study was approved by the Institutional Review
Board at NSLIJHS and Partners Healthcare.
Genotyping
All samples were genotyped using the ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems, Foster
City, CA). The 5' nuclease assay (TaqMan®) was used to
distinguish the two alleles of a gene. PCR amplification
was carried out on 5–20 ng DNA using 1 × TaqMan® uni-
versal PCR master mix (No Amp-erase UNG), 900 nM for-
ward and reverse primers, 200 nM of the FAM labeled
probe and 200 nM of the VIC labeled probe in a 5 ul reac-
tion volume. Amplification conditions on an AB 9700
dual plate thermal cycle (Applied Biosystems, Foster City,
CA) were as follows: 1 cycle of 95°C for 10 min, followed
by 50 cycles of 92°C for 15 s and 58°C for 1 min. Taq-
Man® primers and probes were designed using the Primer
Express® Oligo Design software v2.0 (ABI PRISM) or using
the ABI Assays-By-Design service.
Statistical Analyses
Tests of Hardy-Weinberg equilibrium (HWE) were per-
formed at each SNP locus [48]. Application of the test for
HWE was restricted to the control samples from each eth-
nic group as a means of identification of genotyping prob-
lems. Single SNP analyses: Statistical inference for single
SNP associations was based on Chi-square test statistics.
For each SNP an allelic association test and the Cochran-
Armitage trend test (test for additive allelic effects) were
performed [49]. Haplotype analyses: Haplotype associa-
tions were explored using score tests that account for link-
age phase ambiguity [50]. The score tests, derived from
generalized linear models, are used for global tests of asso-
ciation, as well as haplotype-specific tests. In addition, a
permutation algorithm was applied in the testing frame-
work to find the maximum of the haplotype-specific score
statistics and its associated p-value. The haplo.stats pro-
gram implements the methods of Schaid et al. [50] and
was used for these analyses. Haplotypes were imputed
and frequencies estimated using the EM-algorithm-based
estimation facility in haplo.stats.
Results
Single SNP analyses
We tested four COMT SNPs (-278 A/G, rs737865, Val108/
158Met and rs165599) for association with diagnosis in
our sample of 394 US-Caucasian cases and 467 controls.
All SNPs were in HWE (data not shown). The results of the
single SNP analysis are presented in Table 1. Three of the
four SNPs were significantly associated with our broad
"all affecteds" diagnosis: -278 A/G (p = 0.004; OR = 1.34),
Val108/158Met (p = 0.05; OR = 1.21) and rs165599 (p =
0.035; OR = 1.25). When the cases were restricted to
patients with schizophrenia or schizoaffective disorder (n
= 258), only the promoter polymorphism (-278 A/G)Behavioral and Brain Functions 2005, 1:19 http://www.behavioralandbrainfunctions.com/content/1/1/19
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remained significant (p = 0.015; OR = 1.33). This SNP
also remained significant when only patients with schizo-
phrenia were included (n = 196; p = 0.011, OR = 1.39).
None of the SNPs yielded significant p-values in the group
of patients with schizoaffective disorder (n = 62; data not
shown). In the set of patients who were diagnosed with an
affective disorder (n = 112; 82 bipolar disorder, 30 major
depressive disorder), significant p-values were obtained
for the G (Val) allele of the Val/Met polymorphism (p =
0.018; OR = 1.43) and the G allele of rs165599 (p = 0.039;
OR = 1.38). The A allele of SNP -278A/G showed a trend
for significance in this group (p = 0.062; OR = 1.34).
When broken down into subcategories, -278A/G was mar-
ginally associated in the major depressive group (n = 30;
p = 0.046; OR = 1.79) and Val158Met showed a trend
towards association in the group of bipolar patients (n =
82; p = 0.058, OR = 1.39). Overall evidence for associa-
tion was most robust for the promoter polymorphism -
278 A/G.
Marker-to-Marker Linkage Disequilibrium
Linkage disequilibrium (LD) between the four SNPs was
assessed in cases and controls via Lewontin's D' statistic
(Table 2). The markers span 28.5 kb on genomic DNA. In
general, LD was higher between markers located in the 5'
region of the gene. SNP -287 A/G is located only 2 kb from
SNP rs737865 and is in complete LD with it. LD was also
high for marker pair rs737865 – Val/Met. SNP rs165599
showed modest LD with the Val/Met polymorphism. This
pattern is consistent with previous reports [40,45]. In con-
trast, a recent study by Chen et al. found only modest LD
between rs737865 and the Val/Met polymorphism [22].
Table 1: Allele frequencies
All affecteds* SCZ + SA
SNP ID (dbSNP No) Alleles 
(major/
minor) *
MAF 
Controls
MAF 
Cases
p-value Trend 
p-value
OR (95%CI) MAF 
Controls
MAF 
Cases
p-value Trend 
p-value
OR (95%CI)
n = 467 n = 394 n = 467 n = 258
rs2097063 (287A/G) A/G 0.414 0.346 0.004 0.006 1.34 (1.10, 1.64) 0.414 0.347 0.015 0.019 1.33 (1.06, 1.67)
rs737865 T/C 0.309 0.332 0.315 0.321 1.11 (0.90, 1.37) 0.309 0.329 0.438 0.448 1.10 (0.87, 1.39)
rs4680 (Val/Met) A/G 0.475 0.524 0.050 0.048 1.21 (1.00, 1.47) 0.475 0.504 0.304 0.299 1.12 (0.90, 1.40)
rs165599 A/G 0.326 0.376 0.035 0.040 1.25 (1.02, 1.53) 0.326 0.364 0.160 0.175 1.18 (0.94, 1.49)
SCZ Affective disorder*
SNP ID (dbSNP No) Alleles 
(major/
minor) *
MAF 
Controls
MAF 
Cases
p-value Trend 
p-value
OR (95%CI) MAF 
Controls
MAF 
Cases
p-value Trend 
p-value
OR (95%CI)
n = 467 n = 196 n = 467 n = 112
rs2097063 (287A/G) A/G 0.414 0.338 0.011 0.014 1.39 (1.08, 1.79) 0.414 0.346 0.062 0.067 1.34 (0.98, 1.82)
rs737865 T/C 0.309 0.327 0.511 0.518 1.09 (0.84, 1.41) 0.309 0.329 0.560 0.556 1.10 (0.80, 1.50)
rs4680 (Val/Met) A/G 0.475 0.500 0.419 0.414 1.10 (0.87, 1.41) 0.475 0.565 0.018 0.015 1.43 (1.06, 1.93)
rs165599 A/G 0.326 0.362 0.221 0.240 1.17 (0.91, 1.51) 0.326 0.400 0.039 0.043 1.38 (1.02, 1.87)
Major depressive disorder BP
SNP ID (dbSNP No) Alleles 
(major/
minor) *
MAF 
Controls
MAF 
Cases
p-value Trend 
p-value
OR (95%CI) MAF 
Controls
MAF 
Cases
p-value Trend 
p-value
OR (95%CI)
n = 467 n = 30 n = 467 n = 82
rs2097063 (287A/G) A/G 0.414 0.283 0.046 0.049 1.79 (1.01, 3.18) 0.414 0.369 0.280 0.290 1.21 (0.86, 1.71)
rs737865 T/C 0.309 0.333 0.688 0.689 1.12 (0.64, 1.95) 0.309 0.327 0.638 0.634 1.09 (0.76, 1.56)
rs4680 (Val/Met) A/G 0.475 0.586 0.101 0.093 1.56 (0.91, 2.68) 0.475 0.557 0.058 0.050 1.39 (0.99, 1.95)
rs165599 A/G 0.326 0.414 0.169 0.184 1.46 (0.85, 2.51) 0.326 0.395 0.088 0.095 1.35 (0.96, 1.91)
* All Affecteds: SCZ (schizophrenia), SA (schizoaffective disorder), BP (bipolar disorder), Major depressive disorder, psychotic disorder NOS, 
depressive disorder NOS
* Affective Disorder: Bipolar disorder and major depressive disorderBehavioral and Brain Functions 2005, 1:19 http://www.behavioralandbrainfunctions.com/content/1/1/19
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With the exception of the Val/Met – 737865 marker pair,
D' values were similar in the schizophrenia/schizoaffec-
tive disorder group and the affective disorder group. In the
latter, the Val/Met was in complete LD with rs737865,
which may have contributed to the differences in the sta-
tistical difference observed for this SNP.
Haplotype analyses
Shifman et al. described a highly significant association of
a three-site haplotype consisting of the G allele of SNPs
rs737865, Val/Met and rs165599. This haplotype was
associated with schizophrenia and bipolar disorder
[33,40]. We constructed four-marker haplotypes for the
Caucasian group including -278 A/G and the three SNPs
present on the Shifman haplotype. Ten haplotypes had
estimated frequencies above 0.025 and were included in
the association testing (Table 3). This large number is
most likely due to the low LD of rs165599 with the other
three markers. One haplotype (G-A-A-A) was significantly
underrepresented in cases and could be protective (p =
0.0033; maximum haplotype specific p = 0.026). Haplo-
type frequencies of the "opposite" haplotype (A-G-G-G),
which encompasses the "Shifman haplotype did not differ
significantly in the all affecteds group (Table 3), or any of
the subgroups (data not shown). In contrast, the poten-
tially protective G-A-A-A haplotype remained significantly
underrepresented in most subgroups (Table 4).
Discussion
The COMT gene has been extensively studied as a candi-
date gene for a variety of psychiatric disorders including
schizophrenia, bipolar disorder, and other psychiatric
conditions because of 1. Its known function in dopamine
metabolism 2. The presence of a common functional non-
synonymous SNP in exon 4 (Val/Met), which alters
enzyme activity and 3. Its location in the region com-
monly deleted in VCFS/DGS, which is associated with
severe psychiatric disease often diagnosed as schizophre-
nia. However, no consistent picture has yet emerged,
which might in part be due to small sample size of many
studies.
We hypothesized that variation at the COMT locus con-
fers a general basic risk for developing neuropsychiatric
disease and therefore genotyped several variants in a het-
erogeneous group of patients. Several studies support this
hypothesis: Results from family, twin, linkage and
association studies show an overlapping genetic etiology
of schizophrenia and bipolar disorder [reviewed in: [51]].
Several "overlap genes" including G72/G30 [52-55], Neu-
regulin [56,57] and DISC1 [58] have now been associated
with both schizophrenia and bipolar disorder.
In addition, family studies have also shown evidence for
an overlap between the genetic etiologies of schizophre-
nia and major depressive disorder: For example, the inci-
dence of major affective disorder (bipolar and unipolar)
was increased in relatives of probands with schizophrenia
or schizoaffective disorder [59]. Data from another study
supports the view that there could be a familial relation-
ship between the predispositions to schizophrenia and to
major depression as SCZ probands had an increased
familial risk for unipolar major depressive disorder [60].
The SNPs genotyped in our sample included the well-
known Val/Met variant, two SNPs that were highly associ-
ated in a previous study (rs737865 and rs165599 [40]) as
well as -287A/G, a polymorphism in the P2 promoter.
Three SNPs (-278A/G, Val/Met and rs165599 A/G) were
associated in this broad diagnostic group with -278 A/G
showing the most significant p-values. Haplotype
revealed the existence of a potentially protective haplo-
type (G-A-A-A), which was significantly underrepresented
in our all affecteds category and remained significant in
most analyzed subgroups. The haplotype consisting of the
"opposite" alleles of the risk haplotype described by Shif-
man et al. [33,40] was not significantly overrepresented in
our cases.
Our results add to the growing number of studies showing
an association of the Valine allele of the Val108/158 Met
polymorphism, the only proven functional COMT variant
so far. Interestingly, a comparison of risk haplotypes
Table 2: Linkage Disequilibrium (D')
Controls rs737865 Val/Met rs165599
-287A/G 1 0.57 0.37
rs737865 0.72 0.23
Val/Met 0.67
Affected rs737865 Val/Met rs165599
-287A/G 1 0.51 0.27
rs737865 0.85 0.21
Val/Met 0.65
SCZ/SA rs737865 Val/Met rs165599
-287A/G 1 0.53 0.32
rs737865 0.76 0.28
Val/Met 0.64
Affective Disorder rs737865 Val/Met rs165599
-287A/G 1 0.53 0.29
rs737865 1 0.23
Val/Met 0.52Behavioral and Brain Functions 2005, 1:19 http://www.behavioralandbrainfunctions.com/content/1/1/19
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identified in previous studies showed that, even though
the individual haplotypes vary with respect to the combi-
nation of alleles, all contain the Valine allele, indicating
that it may be much older than their division [Figure 1
and references [22,24,27,33,40]].
In addition to the heterogeneous "all affecteds" category,
we separately analyzed cases with psychotic and affective
illness to analyze the contribution of the four variants to
disease in these subgroups. In the psychotic group (schiz-
ophrenia and schizoaffective disorder), only the promoter
variant (-287A/G) remained significant. The other two
SNPs associated in the all affecteds group were not signif-
icant although the allele frequencies still showed an over-
representation of the same alleles. In the affective disorder
group, the association was driven by the 3' portion of the
gene (Val-COMT and rs165599 A/G). The promoter poly-
morphism showed a trend for association in this group.
We suggest that one or a combination of the following fac-
tors might have contributed to these results: First, it is con-
ceivable that COMT harbors more than one functional
variant. Although these may collectively confer a general
risk for neuropsychiatric disease, the magnitude of the
effect may vary depending on diagnosis. Support for this
view comes from a recent family-based study reporting
two separate and interacting effects within a haplotype
spanning rs737865-Val/Met-rs165599 [41]. Second, the
lack of association of some variants in the patients with
affective disorder and not in the SCZ/SA group may be
related to the limitations inherent in a diagnostic system
based upon clinical phenomena, which may not correctly
reflect the underlying biology that predisposes to illness.
Therefore, in the absence of biological markers, a strict
separation of our cohort into schizophrenic and affective
disorder patients may be too stringent [38,39]. Third, we
noted that while the affective disorder group was well
matched with regard to gender (49% male, 51% female),
the schizophrenia/schizoaffective group showed an excess
of males (67%). This imbalance may have contributed to
the lack of association of Val/Met and rs165599 as schiz-
ophrenia may have gender-specific differences [61,62]
and previous studies suggested a stronger association of
the G (Val) allele or a Val-containing haplotype in females
[25,40]. It has also been suggested that the Val/Met vari-
ant does not contribute to disease but is merely in high LD
with the actual functional variant [40,41]. We observed
different D' values for the Val/Met – rs737865 marker pair
in the analyzed patient subgroups which may have con-
tributed to the differences in the statistical significance of
the Val/Met SNP.
Finally, one could argue that our results were influenced
by hidden population substructure, leading to false posi-
tive results. However, while this is a possible limitation of
our study, empirical data obtained from US-Caucasian,
African American and European populations suggest that
carefully matched studies of moderate size are unlikely to
contain significant stratification levels [63,64]. In particu-
lar, a recent study by Tang et al. showed that self-identified
ethnicity is the major determinant of genetic structure in
the United States [65].
Table 3: Haplotypes observed in the "all affecteds" group
287A/G (A/G) rs737865 (A/G) Val/Met (A/G) rs165599 (A/G) Frequency 
(cases)
Frequency 
(controls)
Haplotype-
specific p-values
G A A A 0.2226 0.2809 0.0033
A G G G 0.1763 0.1489 0.1212
AAAA 0 . 1 6 2 9 0 . 1 4 4 6 0 . 2 7 8 4
A G G A 0.1261 0.1191 0.7400
A A G G 0.0829 0.0807 0.3639
G A G G 0.0548 0.0385 0.3524
A A G A 0.0538 0.0386 0.2169
G A A G 0.0424 0.0462 0.8213
GAGA 0 . 0 2 8 2 0 . 0 4 9 0 0 . 0 8 8 4
A G A A 0.0300 0.0418 0.2253
Table 4: Frequency of the G-A-A-A haplotype
cases controls Haplotype-specific p-values
All 0.2226 0.2809 0.0033
SCZ+SA 0.2282 0.2809 0.0191
SCZ 0.2297 0.2809 0.0361
SA 0.2255 0.2809 0.1641
BP + MD 0.2188 0.2809 0.0343
BP 0.2383 0.2809 0.1886
MD 0.1554 0.2809 0.0378Behavioral and Brain Functions 2005, 1:19 http://www.behavioralandbrainfunctions.com/content/1/1/19
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Conclusion
Our study supports a general role of the COMT gene in the
genetic etiology of neuropsychiatric disease including psy-
chotic and affective disorders. Further studies are needed
to unambiguously determine the nature and specific con-
tribution of the functional variant/s.
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